Clinical Trial Update: Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

This update reports results from a Phase 2 trial of ixabepilone in relapsed or refractory aggressive non-Hodgkin lymphoma across multiple subtypes, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Diffuse Mixed Cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Ixempra (ixabepilone)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anaplastic Large Cell Lymphoma, Recurrent Adult Burkitt Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2014-02-27